Takeda Pharmaceutical (TAK) EBITDA Margin (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly EBITDA Margin of 16.51% for Q2 2026, down 17.0% year-over-year from 19.89% in Q2 2025, and little changed quarter-over-quarter from 16.51% in Q1 2026.
Takeda Pharmaceutical (TAK) EBITDA Margin (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's EBITDA Margin history runs 10 years deep, the most recent figure standing at 16.51% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 17.0% year-over-year to 16.51%; the TTM figure through Jun 2026 stood at 5.83% (down 455.0% YoY), while the FY2026 annual figure was 0.14%, down 734.0% from the prior year.
- EBITDA Margin for Q2 2026 stood at 16.51%, roughly flat from 16.51% in the prior quarter.
- The five-year high for EBITDA Margin was 25.56% in Q1 2022, with the low at 38.03% in Q4 2025.
- The 5-year median for EBITDA Margin is 13.86% (2024), against an average of 10.5%.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin jumped 602 bps in 2022, then plunged 3092 bps in 2025.
- Takeda Pharmaceutical's EBITDA Margin stood at 13.4% in 2022, then tumbled by 37 bps to 8.43% in 2023, then slumped by 184 bps to 7.11% in 2024, then sank by 435 bps to 38.03% in 2025, then surged by 143 bps to 16.51% in 2026.
- Business Quant data shows TAK's EBITDA Margin at 16.51% in Q2 2026, 16.51% in Q1 2026, and 38.03% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 3.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.51% |
| Mar 31, 2026 | 16.51% |
| Dec 31, 2025 | -38.03% |
| Sep 30, 2025 | 11.97% |
| Jun 30, 2025 | 16.68% |
| Mar 31, 2025 | 15.28% |
| Dec 31, 2024 | -7.11% |
| Sep 30, 2024 | 11.83% |
| Jun 30, 2024 | 13.77% |
| Mar 31, 2024 | 13.96% |
| Dec 31, 2023 | 8.43% |
| Sep 30, 2023 | 12.51% |
| Jun 30, 2023 | 15.92% |
| Mar 31, 2023 | 15.93% |
| Dec 31, 2022 | 13.40% |
| Sep 30, 2022 | 10.42% |
| Jun 30, 2022 | 15.48% |
| Mar 31, 2022 | 25.56% |
| Dec 31, 2021 | 12.92% |
| Sep 30, 2021 | 11.53% |